Lebrazi J, Elalamy I, Helft G, Samama M M
Service d'Hématologie Biologique, Hôpital Hôtel Dieu, Paris.
J Mal Vasc. 1998 Apr;23(2):92-8.
Staphylokinase which is extracted from Staphylococci has been known for more than 40 years as a profibrinolytic compound. It has been obtained more recently by genetic engineering. Staphylokinase activates plasminogen into plasmin. It is a promising new thrombolytic agent for the treatment of acute myocardial infarction and thromboembolic disease in general. It is a fibrin specific thrombolytic agent which does not decrease plasma fibrinogen level in treated patients. However it is antigenic and the group of Louvain has made much effort to reduce its antigenicity without decreasing its thrombolytic activity. Mutants with a reduced antigenic activity have been recently obtained. These new thrombolytic agents could be superior to currently used drugs. Staphylokinase mutants could have a better benefit/cost ratio than other thrombolytic agents.
从葡萄球菌中提取的葡激酶作为一种促纤溶化合物已有40多年的历史。最近通过基因工程获得了它。葡激酶将纤溶酶原激活为纤溶酶。它一般是治疗急性心肌梗死和血栓栓塞性疾病的一种有前景的新型溶栓剂。它是一种纤维蛋白特异性溶栓剂，不会降低治疗患者的血浆纤维蛋白原水平。然而，它具有抗原性，鲁汶大学的研究团队付出了很多努力来降低其抗原性，同时又不降低其溶栓活性。最近已获得抗原活性降低的突变体。这些新型溶栓剂可能优于目前使用的药物。葡激酶突变体可能比其他溶栓剂具有更好的效益成本比。
